TW202434205A - 環狀gmp-amp合成酶之抑制劑及其用途 - Google Patents

環狀gmp-amp合成酶之抑制劑及其用途 Download PDF

Info

Publication number
TW202434205A
TW202434205A TW112149428A TW112149428A TW202434205A TW 202434205 A TW202434205 A TW 202434205A TW 112149428 A TW112149428 A TW 112149428A TW 112149428 A TW112149428 A TW 112149428A TW 202434205 A TW202434205 A TW 202434205A
Authority
TW
Taiwan
Prior art keywords
compound
alkyl
independently
formula
group
Prior art date
Application number
TW112149428A
Other languages
English (en)
Chinese (zh)
Inventor
拉姆齊 貝弗里奇
傑森 伯奇
史蒂芬 西布拉
派崔克 西爾
Original Assignee
美商凡特斯治療美國公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商凡特斯治療美國公司 filed Critical 美商凡特斯治療美國公司
Publication of TW202434205A publication Critical patent/TW202434205A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW112149428A 2022-12-20 2023-12-19 環狀gmp-amp合成酶之抑制劑及其用途 TW202434205A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263433987P 2022-12-20 2022-12-20
US63/433,987 2022-12-20
US202363501320P 2023-05-10 2023-05-10
US63/501,320 2023-05-10

Publications (1)

Publication Number Publication Date
TW202434205A true TW202434205A (zh) 2024-09-01

Family

ID=89768384

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112149428A TW202434205A (zh) 2022-12-20 2023-12-19 環狀gmp-amp合成酶之抑制劑及其用途

Country Status (12)

Country Link
US (1) US20240270740A1 (https=)
EP (1) EP4638446A1 (https=)
JP (1) JP2026501225A (https=)
KR (1) KR20250131845A (https=)
CN (1) CN120530109A (https=)
AU (1) AU2023408761A1 (https=)
CL (1) CL2025001819A1 (https=)
CO (1) CO2025007987A2 (https=)
IL (1) IL321525A (https=)
MX (1) MX2025007158A (https=)
TW (1) TW202434205A (https=)
WO (1) WO2024137607A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026077404A1 (zh) * 2024-10-10 2026-04-16 北京知维拓医药科技有限公司 一种杂环类化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
EP2934598B1 (en) 2012-12-19 2018-04-18 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
WO2017176812A1 (en) * 2016-04-05 2017-10-12 Immune Sensor, Llc cGAS ANTAGONIST COMPOUNDS
SG11202002218VA (en) * 2017-09-15 2020-04-29 Aduro Biotech Inc Pyrazolopyrimidinone compounds and uses thereof
BR112020016008A2 (pt) 2018-02-05 2020-12-15 The Rockefeller University Composto, método para inibir uma resposta inflamatória em um paciente, método para inibir inflamação em um paciente, método para inibir expressão de interferon ativada por dsdna em um mamífero, método para tratar metástase de câncer em um paciente e formulação farmacêutica
WO2020072492A1 (en) * 2018-10-02 2020-04-09 Baruch S. Blumberg Institute Benzamide derivatives as cgas-sting pathway agonists
JP7781074B2 (ja) * 2020-05-20 2025-12-05 エフ． ホフマン－ラ ロシュ アーゲー Ｃｇａｓ阻害トリアゾロピリミドン誘導体
EP4267571A1 (en) * 2020-12-22 2023-11-01 Novartis AG Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas
WO2022137085A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Indole derivatives useful in treating conditions associated with cgas
CA3236877A1 (en) * 2021-11-08 2023-05-11 Ventus Therapeutics U.S., Inc. Heterocyclic compounds and uses thereof
CN115160279B (zh) * 2022-07-27 2023-11-24 中国药科大学 苯并吡喃酮类化合物、药物组合物和应用

Also Published As

Publication number Publication date
CN120530109A (zh) 2025-08-22
AU2023408761A1 (en) 2025-06-19
MX2025007158A (es) 2025-07-01
CL2025001819A1 (es) 2025-09-26
WO2024137607A1 (en) 2024-06-27
US20240270740A1 (en) 2024-08-15
JP2026501225A (ja) 2026-01-14
KR20250131845A (ko) 2025-09-03
EP4638446A1 (en) 2025-10-29
IL321525A (en) 2025-08-01
CO2025007987A2 (es) 2025-09-08

Similar Documents

Publication Publication Date Title
US11891365B2 (en) 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
CN114845711B (zh) Raf激酶的抑制剂
CN114929706A (zh) Kras g12c的抑制剂
KR20060132966A (ko) 콜레스테릴 에스테르 운반 단백질 저해제로서의테트라히드로나프티리딘 유도체
CN116783199A (zh) 作为btk抑制剂的吡唑并[1,5-a]吡嗪衍生物
TW202434205A (zh) 環狀gmp-amp合成酶之抑制劑及其用途
EP4651944A1 (en) Inhibitors of cyclic gmp-amp synthase and uses thereof
EP4652164A1 (en) Inhibitors of cyclic gmp-amp synthase and uses thereof
JP2025502899A (ja) Ｂｃｌ－２阻害薬
CN116348472B (zh) 大环化合物
HK1253322B (zh) 作为hdac抑制剂的3-烷基-4-酰氨基-双环[4，5，0]异羟肟酸